abrdn Life Sciences InvestorsHQL
About: abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mostly in securities of Life Sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser, abrdn Inc to have potential for above-average growth.
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
1.5% less ownership
Funds ownership: 35.91% [Q3] → 34.41% (-1.5%) [Q4]
4% less funds holding
Funds holding: 73 [Q3] → 70 (-3) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
16% less capital invested
Capital invested by funds: $148M [Q3] → $124M (-$24.4M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for HQL.
Financial journalist opinion








